Lasa Supergenerics files another suit for permanent injunction against one of its competitors

Filing is aimed to prevent the unauthorised use and disclosure of the confidential information

The manufacturer of veterinary & human APIs, Lasa Supergenerics announced that it has filed suit for a permanent injunction against Lohita Lifescience Pvt Ltd and others restraining infringement of its patent. 

Lasa has filed a suit for permanent injunction restraining infringement of its patent, tortious interference, confidential breach and misuse of information, unfair trading among others, and damages in respect of Indian Patent no 326628 in respect of an invention titled “AN IMPROVED PROCESS FOR THE PREPARATION OF METHYL 5 (PROPYLTHIO)-1H-BENZO [D] IMIDAZOL-2-YLCARBAMATE”, which protects the process for the manufacture of a product named Albendazole. 

Filing is aimed to prevent the unauthorised use and disclosure of the confidential information owned by Lasa to prevent the acts of interference in the business activities, and unfair trading before the Commercial Division of the Bombay High Court against Lohita Lifescience Pvt Ltd and others. 

This may restrain its competitor from manufacturing and dealing in one of the key products and enables the company to continue its leadership for its key products worldwide. 

Further Lasa is also seeking ad-interim reliefs pending the hearing and final disposal of the suit and claiming an amount of Rs 300 crore as compensation for loss of business opportunity and customer at a large scale globally. 

The company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The company has its unit with state of art manufacturing facilities located at Mahad and Chiplun, Maharashtra with a total installed capacity of 4,300 MT. 

The Company has over 25 per cent of APIs exported to counties like Australia, Bangladesh, the Middle East, China, Turkey, Egypt, Jordan, and Korea among othres.